These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11097343)

  • 1. P-glycoprotein and bioavailability-implication of polymorphism.
    Liu Y; Hu M
    Clin Chem Lab Med; 2000 Sep; 38(9):877-81. PubMed ID: 11097343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for P-glycoprotein in environmental toxicology.
    Abu-Qare AW; Elmasry E; Abou-Donia MB
    J Toxicol Environ Health B Crit Rev; 2003; 6(3):279-88. PubMed ID: 12746142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDR1 gene polymorphisms and clinical relevance.
    Li YH; Wang YH; Li Y; Yang L
    Yi Chuan Xue Bao; 2006 Feb; 33(2):93-104. PubMed ID: 16529292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological insights from P-glycoprotein knockout mice.
    Schinkel AH
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):9-13. PubMed ID: 9476142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
    Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.
    Taheri M; Mahjoubi F; Omranipour R
    Genet Mol Res; 2010 Jan; 9(1):34-40. PubMed ID: 20082268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of the MDR-1 gene.
    Mealey KL
    J Vet Pharmacol Ther; 2004 Oct; 27(5):257-64. PubMed ID: 15500562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
    Grauer MT; Uhr M
    J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.
    Constantinides PP; Wasan KM
    J Pharm Sci; 2007 Feb; 96(2):235-48. PubMed ID: 17051593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein activity and biological response.
    Vaalburg W; Hendrikse NH; Elsinga PH; Bart J; van Waarde A
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):257-60. PubMed ID: 16043202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.
    Mealey KL; Waiting D; Raunig DL; Schmidt KR; Nelson FR
    J Vet Pharmacol Ther; 2010 Oct; 33(5):453-60. PubMed ID: 20840389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology.
    Carson SW; Ousmanou AD; Hoyler SL
    Psychopharmacol Bull; 2002; 36(1):67-81. PubMed ID: 12397848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein.
    Yamagishi N; Nakao R; Kondo R; Nishitsuji M; Saito Y; Kuga T; Hatayama T; Nakayama Y
    Biochem Biophys Res Commun; 2014 Jun; 448(4):430-6. PubMed ID: 24796664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution.
    Choong E; Dobrinas M; Carrupt PA; Eap CB
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):953-65. PubMed ID: 20504109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
    Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
    Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations.
    Cascorbi I
    Handb Exp Pharmacol; 2011; (201):261-83. PubMed ID: 21103972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
    Fromm MF
    Int J Clin Pharmacol Ther; 2000 Feb; 38(2):69-74. PubMed ID: 10706193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.